Objective: Adjuvant endocrine therapy (AET) significantly reduces risk of breast cancer recurrence in those patients whose tumor tests hormone (estrogen and/or progesterone) receptor positive. Many who are prescribed AET do not adhere adequately. Studies have sought to examine the effects of interventions to enhance patients' AET adherence, with strikingly mixed results. In order to reconcile a disparate literature, this paper aims to (1) quantitatively review the aggregate effect of interventions designed to optimize AET adherence within the current literature and
tional functioning, 4 and quality of life. 3, 5 Approximately three-quarters of breast tumors test estrogen and/or progesterone receptor positive. 3, [6] [7] [8] For this majority of patients, adjuvant endocrine therapy (AET) is a crucial component of effective treatment. AET disrupts breast tumors' access to these hormones, increasing disease free survival rates by reducing risk of recurrence. 4, 7, 9 Deceptively simple in a one-pill, single daily dose formulation, AET adherence can nonetheless present significant complexity from the patient perspective. 8 Observational studies report rates of nonadherence from 27% to as much as 69% 10, 11 over the 5-to 10-year span 1, 12, 13 during which AET is routinely prescribed.
Many factors may contribute to breast cancer survivors' AET nonadherence. These include demographic variables such as increased age, 14 psychological factors of attitude and belief, 15, 16 and clinical issues such as side effect burden. 17, 18 Although each of these carries the potential for influence, the current literature is not yet in agreement when attempting to quantify their relative contributions. A recent systematic review 19 concluded that the existing empirical evidence for social and psychological predictors of adherence and persistence to AET are weak or inconsistent. That said, the existing literature appears to trend in favor of patients' values, self-efficacy, and financial situation having rather intuitive effects on adherence and persistence to AET-belief in the necessity 20, 21 and importance 22 of the treatment have been found to predict greater adherence, and positive and negative emotions have been found to predict greater and lesser adherence, respectively. 21 Patients who fear recurrence of their cancer persist with AET for longer, 23 while patients who value future fertility are more likely to discontinue treatment. 24 Greater self-efficacy in the ability to communicate with one's physician, 25 take medication, 26, 27 and learn about medication all tend to predict greater adherence to AET, as does a positive relationship with one's physician. 21 Financial distress, 21 low income, 28 and higher monthly health costs [28] [29] [30] [31] have been found to predict poorer adherence to AET. The effects of general psychological health are less clear-while anxiety may predict shorter persistence with AET, 32 depression has been found to predict both longer 33, 34 and shorter 24 persistence. Given both the significant rates of nonadherence and the multiple factors that may influence it, there is great value in developing and testing interventions to optimize AET adherence in this population.
Interventions to promote adherence to AET in breast cancer survivors vary in both design and reported efficacy. This heterogeneity introduces error and makes it difficult for investigators to plan and propose effective future intervention designs. Given its identification as a funding priority, and the growing number of proposals and protocols seeking to address this question, there is a pressing need for greater understanding of oral anticancer therapy adherence. The present study contributes to the existing literature by providing a systematic quantitative review and meta-analysis of interventions to promote adherence to adjuvant AET in breast cancer patients.
2 | METHODS
| Data collection
Multiple strategies were used to identify relevant studies. Two independent researchers conducted Boolean searches for publications in the PubMed/Medline, PsycINFO, and CINHAL electronic databases.
We developed our search terms from three core concepts (hormone therapy, medication adherence, and breast cancer) and included permutations of the following search terms: ("Estrogen Antagonists" OR "Antineoplastic Agents" OR "Anti-cancer agents" OR "Tamoxifen" OR "SERM" OR "Aromatase Inhibitors" OR "AI" OR "Endocrine Therapy"
OR "Hormone Therapy") AND ("Medication adherence" OR "Patient Studies that met the following a priori criteria were included in this review: (1) tested an intervention to promote AET adherence, (2) reported at least one measure of medication adherence, and (3) reported data sufficient to calculate effect size (ES). Whenever a study met criteria (1) and (2) but did not report sufficient data for ES calculation, we contacted the corresponding author to request the necessary information.
| Coding of interventions
Using a standardized, pilot tested coding form (see Supporting Information), two reviewers independently coded abstracted study data including general information (eg, study location, year of data collection), participant characteristics (eg, age, gender, and race/ethnicity), design elements, and statistical data for ES calculation. Coders displayed an acceptable rate of agreement (agreement rate: 91.05%; weighted κ = 0.834, P < 0.001). Discrepancies were reconciled through discussion.
| Risk of bias
It is helpful for a systematic review to include descriptions of included studies' methodological quality 35 in order to assess for risk of bias within individual studies. 36 To this end, we used Downs and Black's 37 methodological quality scale, a 27-item instrument that assesses five dimensions of research methodology: reporting bias, external validity, measurement bias, confounding (selection bias), and statistical power.
Two independent raters showed substantial strength of agreement in their use of the instrument (κ = 0.822; P < 0.001). We report each of the instrument's five subscales separately in order to provide a clearer appraisal of individual methodological elements than may be gained by a summary score. 36 We also sought to assess the risk of publication bias favoring studies demonstrating greater intervention effects as well as any asymmetry of the distribution due to any other reason, eg, outliers and considered use of plotting strategies (funnel plot) and correlational approaches (Begg's and Egger's tests) where appropriate, given the known limitations of these methods. All elements of this research are reported in accordance with the statement on Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA). 38 
| Analytic approach
ESs were estimated using the standardized mean difference d.
39-41
Some studies reported multiple adherence measurements and multiple time points. When multiple measurements were made of the same sample of participants, in the same study, the different resulting ESs were averaged within that study before aggregating ESs between studies. ESs and inverse variance weights for each outcome were calculated, 42 and final meta-analytical tests of derived ESs were performed using the software R with R packages Mad 43 and metaphor. 44 We calculated weighted mean ESs to estimate overall strength of intervention on medication adherence, then analyzed these using random-effects assumptions with the magnitude of heterogeneity across ESs assessed using the I 2 statistic and its confidence interval. 45, 46 Sensitivity analyses using the Q statistic as a measure of variance in a meta-analytic analog to the one-way analysis of variance (ANOVA) 47 assessed whether intervention design characteristics explained variability in the impact on endocrine therapy (ET) adherence. All characteristics of this meta-analysis are reported using PRISMA guidelines. 48 3 | RESULTS
| Literature search outcomes
Our searches returned 1207 articles for potential inclusion. After reviewing title and abstract, 1083 studies were excluded as false hits or duplicate results. Of the remaining 124 studies initially retained, 118 were studies that did not measure ET adherence and/or did not report quantitative analyses, ie, qualitative studies. The remaining six full-text articles and one conference abstract met inclusion criteria; however, the conference abstract did not report sufficient data. This investigator responded to our written request with the necessary additional data to allow the study's inclusion (see Figure 1 ). This meta-analysis reflects a final set of seven reports describing eight interventions to promote ET medication adherence among breast cancer survivors. Listings of excluded studies with rationale are available as Supporting Information. 
| Study characteristics

| Participant characteristics
This meta-analysis represents a total of 4698 consented female subjects who were retained to one or more follow-up assessments. Studies reported the proportion of women who completed study procedures to at least one follow-up for an average completion rate samples; the remainder reported a minority (less than 15%) of participants whose use of AET preceded their study enrollment.
| Design characteristics
Most (k = 7) interventions used a control group comparison, while one 34 employed a single group design. Studies 48, 49, 51 reported data at 2 years, at 1 year, 47, 52 and shorter-term follow-up data collection. 50, 53 The definition of adherence was largely uniform across studies with most (k = 6) defining adherent as ≥80% of scheduled doses.
Studies varied in their methods of measuring adherence and most (k = 6) studies attempted to capture medication adherence behavior by multiple means (mean = 2.23) using self-report (k = 6) and either pharmacy refill data (k = 3) or provider report (k = 3). 
| Intervention characteristics
| Did intervention characteristics influence ESs?
In testing methodological factors, we considered the possible contri- 3.8 | What was the risk of bias within individual studies or among the body of included studies? Table 2 quate numbers of included trials to properly assess a funnel plot or more advanced regression-based assessments; therefore, publication bias was not assessed quantitatively using these methods.
| DISCUSSION
This paper summarizes the available literature on interventions to promote adherence to AET among breast cancer survivors. It further provides a meta-analysis of studies' findings and offers a sensitivity analysis of how study design may influence intervention ES: to our knowledge, this paper is the first to do so.
Our analyses show that interventions failed when using on a oneway flow of communication, relying on primarily informational approaches to enhance AET adherence. Conversely, bidirectional interventions, ie, those that elicited information from patients as well as send information to patients, reported greater adherence in the intervention group relative to control.
| Clinical implications
We feel that our research has particular implications for the provision SDT theory postulates that relatedness, or a sense of meaningful connection to others, predicts the successful development of effective behaviors. 55 The two-way, give and take of bidirectional elicitation approaches in study designs may have tapped this construct in evincing superior rates of medication adherence, imparting a feeling of greater connection between patient and provider.
The implications of these analyses may reach beyond AET for breast cancer as more and more oral anticancer therapies are tested and used. Unlike intravenous chemotherapy that is directly observed, oral anticancer therapies are typically pill based, daily regimens that like AET must be adhered to in order to achieve an optimal clinical outcome. This underscores the emerging importance of how we measure medication adherence in oncology.
| Study limitations
While the current study presents findings of potential interest, these must be considered in light of its particular limitations. Foremost among these is sample size (k). The small number of included studies in this meta-analysis must necessarily introduce caution when considering the generalizability of its estimates. We sought to keep inclusion criteria as broad as possible while still including only relevant studies.
By assessing the gray literature, we sought to mitigate any risk of publication bias; however, the still small literature to address this specific adherence issue within the field is noteworthy. While small in number, the studies included in this meta-analysis represent nearly 5000 participants from over 20 countries. Given the clinical importance of the subject, and the current number of new designs and funding proposals attempting to address the issue of oral medication adherence in oncology, we felt it was both valuable and timely to present these analyses.
Nonetheless, these findings must be seen as preliminary. Abbreviations: EV, external validity; IV, internal validity; P, power; RB, reporting bias; SB, sampling bias.
The design limitations among included studies also extend to the overall review. The majority of studies' interventions did not cite any theory of behavior change as underpinning their work. AET is routinely prescribed for 5 to 10 years. While all studies used a longitudinal design, the longest studies followed participants for 2 years after enrollment.
Because the likelihood of nonadherence increases with time, this may have contributed to a restriction of range in the variation of adherence data between groups. As methodological quality ratings for these studies
show, most studies exhibited inadequate statistical power and limited external validity. Both types of limitation are likely to be present in early intervention trials. That most included studies exhibited these higher risks of bias again underscores the paucity of research in this specific area and emphasizes the need for more intervention development and largescale replication studies. The ES calculations included in this analysis could serve to guide a priori power analyses and sample size calculations.
Another limitation among these studies was the primary reliance on selfreport to measure adherence. Medication adherence can be measured in many different ways, and as with any scientific method, each approach will naturally introduce some degree of error in its approximation of the true value. 61 Subjective approaches rely on individual persons' report, based on memory, of the degree of medication adherence within a specified time frame. Subjective report measures typically use questionnaires or interview items targeting patients, patient caregivers, or clinicians.
These methods have the clear advantages of minimal cost and ease of use; it is also the most prone to bias. Comparative studies across disease populations and medication types suggest a 10% to 15% inflation rate over more rigorous approaches. 62 Moreover, though there are bettervalidated tools for measuring self-reported adherence, few among the included studies reported these. Thus, the included studies likely reported average levels of AET adherence that are significantly inflated.
This risks creating a ceiling effect, ie, restriction of range with attendant attenuation of the size of the mean difference between study groups. It is therefore possible that we underestimate both the population rates of AET nonadherence and the ES differences across studies in this meta-analysis.
In conclusion, there is considerable room for greater development and testing of interventions to promote AET adherence among breast cancer survivors. Much can by learned by transferring knowledge from established lines of research in other populations, such as HIV.
Researchers are also well advised to adopt theory-based approaches, pursue objective measurements of medication adherence, and consider the influence of bidirectional platforms to optimize adherence in this population.
